Nesfatin-1 in lipid metabolism and lipid-related diseases

Jing-Jing Luo; Feng-Jiao Wen; Dan Qiu; Shu-Zhi Wang

doi:10.1016/j.cca.2021.08.005

Nesfatin-1 in lipid metabolism and lipid-related diseases

Clin Chim Acta. 2021 Nov:522:23-30. doi: 10.1016/j.cca.2021.08.005. Epub 2021 Aug 10.

Authors

Jing-Jing Luo¹, Feng-Jiao Wen², Dan Qiu¹, Shu-Zhi Wang³

Affiliations

¹ Institute of Pharmacy and Pharmacology, School of Pharmaceutical Sciences, University of South China, Hengyang 421001, China; Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421001, China.
² Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Department of Cell Biology and Geneties, University of South China, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China.
³ Institute of Pharmacy and Pharmacology, School of Pharmaceutical Sciences, University of South China, Hengyang 421001, China; Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421001, China. Electronic address: shu-zhi.wang@usc.edu.cn.

PMID: 34389280
DOI: 10.1016/j.cca.2021.08.005

Abstract

Nesfatin-1, an anorexic neuropeptide discovered in 2006, is widely distributed in the central nervous system and peripheral tissues. It has been shown to be involved in the regulation of food intake and lipid metabolism, inhibiting fat accumulation, accelerating lipid decomposition, and in general, inhibiting the development of lipid-related diseases, such as obesity and metabolic syndrome. Potential mechanisms of Nesfatin-1 action in lipid metabolism and lipid-related diseases will be discussed as well as its role as a biomarker in cardiovascular disease. This review expected to provide a new strategy for the diagnosis and prevention of clinically related diseases.

Keywords: Cardiovascular diseases; Fat accumulation; Lipid metabolism; Metabolic syndrome; Nesfatin-1; Obesity.

Publication types

Review

MeSH terms

Calcium-Binding Proteins*
DNA-Binding Proteins
Humans
Lipid Metabolism*
Lipids
Nerve Tissue Proteins
Nucleobindins

Substances

Calcium-Binding Proteins
DNA-Binding Proteins
Lipids
Nerve Tissue Proteins
Nucleobindins